Study S001386

A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06901349
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: WITHDRAWN
Enrollment: 0
Start: 2025-05-23
Primary completion: 2025-06-10
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab Placebo; DRUG:Tirzepatide Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J4Z-MC-GIDI

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, Week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.